北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy
作者: Qin, Ya-Zhen1; Xu, Lan-Ping1; Chen, Huan1; Jiang, Qian1; Wang, Yu1; Jiang, Hao1; Zhang, Xiao-Hui1; Han, Wei1; Chen, Yu-Hong1; Wang, Feng-Rong1; Wang, Jing-Zhi1; Zhu, Hong-Hu1; Liu, Yan-Rong1; Jiang, Bin1; Liu, Kai-Yan1; Huang, Xiao-Jun1,2
关键词: Clinical results ; myeloid leukemias and dysplasias ; prognostication
刊名: LEUKEMIA & LYMPHOMA
发表日期: 2015-11-02
DOI: 10.3109/10428194.2015.1032964
卷: 56, 期:11, 页:3116-3123
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Hematology
研究领域[WOS]: Oncology ; Hematology
关键词[WOS]: MINIMAL RESIDUAL DISEASE ; POLYMERASE-CHAIN-REACTION ; FRENCH AML INTERGROUP ; QUANTITATIVE RT-PCR ; C-KIT MUTATIONS ; RISK STRATIFICATION ; PROGNOSTIC VALUE ; MARROW-TRANSPLANTATION ; CANCER PROGRAM ; GROUP-B
英文摘要:

Eighty-six adult patients with inv(16) acute myeloid leukemia (AML) in first complete remission (CR1) were serially monitored for CBFB-MYH11 transcript levels during the early courses of chemotherapy. Fifty-seven and 29 of them received chemotherapy/autologous stem cell transplant (SCT) and allogeneic (allo-)SCT after second consolidation, respectively. For patients receiving chemotherapy/autologous SCT, the sole independent adverse prognostic factor for the cumulative incidence of relapse (CIR), disease-free survival (DFS) and overall survival (OS) was a CBFB-MYH11 level > 0.2% after course 2 consolidation (p = 0.003, 0.003 and 0.031), which was used to define a poor molecular response (MR). Allo-SCT significantly decreased the 3-year CIR and increased the DFS and OS of patients with a poor MR (p < 0.0001, 0.0001 and 0.045) but did not improve the outcome of patients with good MR (all p > 0.05) compared with chemotherapy/autologous SCT. Therefore, allo-SCT could improve the outcome of adult patients with inv(16) AML in CR1 with a poor MR during the early courses of chemotherapy.

语种: 英语
所属项目编号: Z141100000214011 ; 81170483
项目资助者: Beijing Municipal Science and Technology Program ; Nature Science Foundation of China
WOS记录号: WOS:000365520200019
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/63425
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
2.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China

Recommended Citation:
Qin, Ya-Zhen,Xu, Lan-Ping,Chen, Huan,et al. Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy[J]. LEUKEMIA &amp; LYMPHOMA,2015,56(11):3116-3123.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Qin, Ya-Zhen]'s Articles
[Xu, Lan-Ping]'s Articles
[Chen, Huan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Qin, Ya-Zhen]‘s Articles
[Xu, Lan-Ping]‘s Articles
[Chen, Huan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace